by
In response to the controversy over the research and development and sales profits of the new crown vaccine, the high-end vaccine clarified that the cumulative net sales of the new crown vaccine was 3.62 billion yuan, but from 2020 to the first half of 2022, the research and development and production of the new crown vaccine The expenditure reached 3.35 billion yuan, which is by no means an external mistake. The rumored profiteering, as for the high-end vaccinated people entering Japan, they must hold a negative PCR certificate 72 hours before leaving the country.
High-end vaccines said that since the outbreak of the new crown in early 2020, high-end vaccines immediately negotiated technology transfer with the US National Institutes of Health, and all employees invested in vaccine research and development day and night, conducting a number of preclinical studies and 9 human clinical trials. So far, the new crown vaccine research has been publicly published A total of 16 papers.
High-end vaccines pointed out that 10 papers were published in international journals through peer review. Among them, the expanded phase II clinical research conducted in Taiwan has been published in the world’s top biomedical professional journal “Lancet Respiratory Medicine” (Lancet Respiratory Medicine). , the research and development results are open and transparent, and are recognized by international institutions.
According to the high-end vaccine financial statements, the cumulative net sales of new crown vaccines are 3.62 billion yuan, but from 2020 to the first half of 2022, the total expenditure on research and development and production of new crown vaccines has reached 3.35 billion yuan, including investment in new crown vaccine research and development and clinical trials. 100 million yuan, and the cost of vaccine production is 1.11 billion yuan, and the cumulative investment in research and development and production costs reaches 3 billion to 4 billion yuan, which is not a huge profit from outside misinformation.
High-end vaccines emphasized that high-end will receive 460 million yuan in research and development subsidies from the CDC in 2021, and after obtaining EUA approval, 200,000 doses of vaccine will be given back to the EPA, compared with US$18 billion in vaccine research and development subsidies provided by Operation Warp Speed in the United States Taiwan’s domestic vaccine manufacturers have limited scale and resources, and it is not easy for high-end vaccines to compete with international manufacturers to develop similar products. Please do not believe in false rumors.
As for Japan’s entry-certified vaccines that are not included in high-end vaccines, people must hold a negative PCR certificate 72 hours before going abroad. The command center has developed a supplementary vaccination plan, and plans to allow people who have received high-end vaccines to receive additional vaccines from other brands that meet Japanese regulations. The relevant content will be released as soon as two days.
(Source of the first picture: high-end vaccine)
New technological knowledge, updated from time to time
